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a b s t r a c t
Relaxin is a polypeptide hormone that triggers multiple signaling pathways through its receptor RXFP1
(relaxin family peptide receptor 1).Many of relaxin’s functions, including vascular and antifibrotic effects,
are similar to those induced by activation of PPAR. In this study, we tested the hypothesis that relaxin
signaling through RXFP1 would activate PPAR activity. In cells overexpressing RXFP1 (HEK-RXFP1),
relaxin increased transcriptional activity through a PPAR response element (PPRE) in a concentration-
dependent manner. In cells lacking RXFP1, relaxin had no effect. Relaxin increased both the baseline
activityand the response to thePPARagonists rosiglitazoneand15d-PGJ2, butnot toagonistsofPPARor
PPAR. In HEK-RXFP1 cells infected with adenovirus expressing PPAR, relaxin increased transcriptional
activity through PPRE, and this effect was blocked with an adenovirus expressing a dominant-negative
PPAR. Knockdown of PPAR using siRNA resulted in a decrease in the response to both relaxin and
rosiglitazone. Both relaxin and rosiglitazone increased expression of the PPAR target genes CD36 and
LXR in HEK-RXFP1 and in THP-1 cells naturally expressing RXFP1. Relaxin did not increase PPARmRNA
or protein levels. Treatment of cells with GW9662, an inhibitor of PPAR ligand binding, effectively
blocked rosiglitazone-induced PPAR activation, but had no effect on relaxin activation of PPAR. These
results suggest that relaxin activates PPAR activity, and increases the overall response in the presence
of PPAR agonists. This activation is dependent on the presence of RXFP1. Furthermore, relaxin activates
PPAR via a ligand-independent mechanism. These studies represent the first report that relaxin can
activate the transcriptional activity of PPAR.
Published by Elsevier Ireland Ltd.
1. Introduction
Relaxin is a polypeptide hormone of the insulin superfam-
ily, which also includes the relaxin-like peptides relaxin-3 and
insulin-like peptide-3 (InsL3) (Sherwood, 2004). Despite consid-
erable structural similarity to insulin, relaxin does not bind to the
insulin receptors and has no insulin-like glucocoregulatory effects.
The identification of a relaxin receptor proved elusive, which ham-
pered progress in relaxin research for many years, until Hsu et al.
identified two relaxin receptors in 2002. Somewhat surprisingly,
unlike the receptors for insulin and insulin-like growth factor I,
which signal through tyrosine kinase receptors, the leucine-rich G
protein-coupled receptors 7 and 8 (LGR7 and LGR8) were identi-
∗ Corresponding author at: Research Service (151), VA Medical Center, 4101
Woolworth Ave., Omaha, NE 68105, United States. Tel.: +1 402 995 3360;
fax: +1 402 449 0604.
E-mail address: rgbennet@unmc.edu (R.G. Bennett).
fied as relaxin receptors (Hsu et al., 2002). These receptors are now
known as relaxin family peptide receptor (RXFP) 1 and 2, respec-
tively (Bathgate et al., 2006). Although relaxin will bind to and
activate both receptors in vitro, the evidence thus far suggests that
only RXFP1 is activated by relaxin in vivo, and therefore RXFP1 is
considered to be the cognate relaxin receptor, while RXFP2 is the
InsL3 receptor.
Activation of RXFP1 stimulates adenylyl cyclase and increases
cAMP through a complex, biphasic mechanism (Halls et al., 2006;
Nguyen et al., 2003). Initially, RXFP1 couples to Gs, resulting in
rapid increase in cAMP (Halls et al., 2006). This is followed by cou-
pling to Go and a transient decrease in cAMP production, then
finally a delayed and sustained increase in cAMPmediated through
coupling to Gi and activation of phosphoinositide 3′-kinase and
protein kinase C throughG/ subunits (Halls et al., 2006;Nguyen
et al., 2003). In addition to stimulation of cAMP, a number of other
pathways can also be triggered by relaxin signaling. Relaxin effects
in a number of tissues are mediated by stimulation of nitric oxide
synthase and increased nitric oxide production (Baccari and Bani,
0303-7207/$ – see front matter. Published by Elsevier Ireland Ltd.
doi:10.1016/j.mce.2009.08.014
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2008). In some cells, relaxin can activate the extracellular signal-
related kinase 1 and 2 (ERK1/2) pathway, in a process that may
involve the nuclear factor NF-B (Dschietzig et al., 2003; Ho et al.,
2007; Zhang et al., 2002;Mookerjee et al., 2009). Additional studies
have suggested that relaxin can activate a tyrosine kinase path-
way in some cells (Anand-Ivell et al., 2007; Bartsch et al., 2001;
Palejwala et al., 2001). There is also a report that relaxin can acti-
vate the glucocorticoid receptor through a mechanism that may
be independent of RXFP1 (Dschietzig et al., 2005). Therefore, the
accumulating evidence suggests that relaxin signals throughhighly
diverse and complex mechanisms.
The traditional functions attributed to relaxin are related
to pregnancy, where its functions include inhibition of uterine
contraction, and inducement of cervical growth and softening
(Sherwood, 2004). However, recent studies have revealed that
relaxin has many nonreproductive functions. It has been long
known that relaxin has antifibrotic effects related to its ability to
regulate the expression and degradation of extracellular matrix
components. In fibroblasts and myofibroblasts, relaxin inhibits
transforming growth factor beta (TGF-)-induced collagen pro-
duction and promotes matrix degradation, and decreases fibrillar
collagen in experimental models of dermal, pulmonary, renal, and
hepatic fibrosis (Samuel, 2005). This property was strongly sup-
ported by studies of the relaxin-null mouse. These mice developed
age-related fibrosis in a number of tissues including the lung, skin,
heart, and kidney (Samuel et al., 2005), suggesting a role for relaxin
in the treatment of fibrosis, and in the prevention of the develop-
ment of age-related fibrosis. In addition, relaxin exhibits properties
related to the control of cardiovascular functions. Relaxin promotes
vasodilation and angiogenesis, protects against ischemic damage,
and displays anti-inflammatory properties, largely through nitric
oxide-dependent pathways (Bani, 2008; Baccari and Bani, 2008).
Therefore, in addition to its reproductive role, relaxin is an impor-
tant modulator of a number of physiological processes outside of
pregnancy. Many of these nonreproductive functions of relaxin
are similar to those regulated by peroxisome proliferator-activated
receptor gamma (PPAR).
The peroxisome proliferator-activated receptors (PPARs) are
nuclear receptors that heterodimerize with the retinoid X recep-
tors (RXR) to induce transcription of target genes (Evans et al.,
2004). Three major PPARs have been identified to date. PPAR,
the earliest identified form, is involved in peroxisome prolifera-
tion and lipid utilization. Less is known about PPAR (also known
as PPAR), but its main functions appear to be in fatty acid utiliza-
tion. The third form, PPAR is a major regulator of adipogenesis
(Tontonoz and Spiegelman, 2008). Agonists of PPAR, such as the
antidiabetic thiazolidinedione drugs, promote lipid storage in adi-
pose tissue, decrease serum lipid levels, and regulate adipokine
secretion from the adipose tissue, and increase insulin responsive-
ness in the liver and muscle (Tontonoz and Spiegelman, 2008).
In addition, PPAR agonists have antifibrotic properties in the
skin, heart, kidney, lung and liver (Calkin et al., 2006; Genovese
et al., 2005; Iglarz et al., 2003; Wu et al., 2009; Galli et al.,
2002), and induce anti-inflammatory, cardiovascular, and antifi-
brotic effects (Tontonoz and Spiegelman, 2008; Varga and Nagy,
2008).
Because relaxin and PPAR share a number of biological effects,
it is possible that theypossess commonsignalingpathways. Relaxin
stimulates the production of cAMP and nitric oxide, both regula-
tors of PPAR activity (Lazennec et al., 2000; Ptasinska et al., 2007;
Watanabe et al., 2003). Therefore, it is possible that activation of
PPARmay be onemechanism for the antifibrotic effects of relaxin.
We hypothesized that relaxin activation of RXFP1 would result in
increased PPAR activity. To explore this possibility, we sought to
determine the effect of relaxin on the levels and activity of PPAR
in cells expressing RXFP1.
2. Materials and methods
2.1. Materials
Highly purified porcine relaxin (Sherwood and O’Byrne, 1974) was provided by
O.DavidSherwood (Universityof IllinoisUrbana-Champaign). TheRXFP1expression
plasmid (Hsu et al., 2000) was provided by Aaron Hsueh (Stanford University). The
PPAR luciferase reporter plasmid ACO-PPRE (Jiang et al., 1998) was provided by
Brian Seed (Harvard University). Adenoviruses expressing wild-type and mutant
PPAR and -galactosidase (Park et al., 2003) were provided by J. Larry Jameson
(Northwestern University). Human relaxin-3 (H3 relaxin) and insulin-like peptide
3 (InsL3) were from Phoenix Pharmaceuticals. Rosiglitazone, GW0742, GW9662,
and 15-12,14-deoxy prostaglandin J2 (15d-PGJ2) were from Cayman Chemical.
WY-14,643 was from Sigma Chemical.
2.2. Production of cell lines stably expressing RXFP1
To generate cells stably expressing RXFP1, a plasmid encoding LGR7/RXFP1
containing a FLAG epitope (Hsu et al., 2000) was transfected into HEK-293T cells
(American Type Culture Collection) using Fugene-6 according to themanufacturer’s
instructions. Cells stably expressing the FLAG-RXFP1 were selected using zeocin
(Invitrogen) at 400g/mL, and individual clones were isolated and screened for
RXFP1 expression using an in-cell Western blot procedure. Cells grown on poly-l-
lysine coated 96-well plates were fixed in 4% paraformaldehyde for 20min, then
washed and solubilized in PBS containing 0.1% Triton X-100 for 5min for a total of
5 washes. After blocking in Odyssey block (Li-Cor) for 2h, wells were incubated
with either M2 anti-FLAG antibody (Sigma) or an antibody to a control protein
(rabbit anti-insulin-degrading enzyme, Millipore) at a 1:1000 dilution in Odyssey
block overnight at 4 ◦C. After washing 5 times with PBS containing 0.1% Tween-20
for 5min each, the cells were incubated in the dark with IRDye-680 labeled goat
anti-rabbit or IRDye-800 labeled goat anti-mouse secondary antibodies for 1h at
room temperature. After 5washeswith PBS containing 0.1% Tween-20 and one final
PBS wash, fluorescence was measured in an Odyssey infrared fluorescence scanner
(Li-Cor). The clones with the highest FLAG content relative to the control protein
were selected and expanded. The cells were then screened for relaxin responsiv-
ity (cAMP production), and a final clone (HEK-RXFP1) was selected and used for all
studies.
2.3. Reporter and cAMP assays
PPARactivationwasmonitoredusingadual-luciferase reporter assay. Cellswere
transfected with a plasmid (ACO-PPRE) containing three copies of the acyl-CoA oxi-
dase PPRE element upstream of the firefly luciferase gene (Jiang et al., 1998), and
a plasmid containing the renilla luciferase gene under the control of the thymi-
dine kinase promoter (pRL-TK, Promega) to control for transfection efficiency and
cell number. After 24h, cells were treated and incubated for 24h, and then firefly
and renilla luciferase activities were measured using the Dual-Glo assay (Promega).
For cAMP determinations, cells were treated for 30min at room temperature, and
cAMP content was determined using the cAMP-Glo assay (Promega) following the
manufacturer’s instructions.
2.4. Overexpression and knockdown of PPAR
To increase expression of PPAR, HEK-RXFP1 cells were infected with a total
of 45 ifu of replication-incompetent adenovirus containing the genes for -
galactosidase (-Gal), wild-type PPAR, or dominant-negative Leu466Ala-PPAR
(Park et al., 2003). After 24h, cells were transfected with ACO-PPRE and pRL-
TK plasmids, treated with relaxin or rosiglitazone for 24h, then subject to the
PPRE luciferase reporter assay as described above. For knockdown of PPAR, siRNA
and reporter plasmids were applied to HEK-RXFP1 cells using Nucleofection Kit V
(Amaxa) as directed by the manufacturer. Each nucleofection reaction contained
2g siRNA (either PPAR siRNA or nontargeting control SMARTpool siRNA, Dhar-
macon), 1g ACO-PPRE and 0.1g pRL-TK. After nucleofection, cells were seeded
ontopoly-l-lysine coated96-well or 24-well plates. After 24h, cells in 96-well plates
were treatedwith relaxinor rosiglitazone for24h, then subject to thedual-luciferase
assayasdescribedabove.Cells in24-wellplateswere lysedandknockdownofPPAR
was verified using anti-PPAR (Santa Cruz) and anti-GAPDH (Millipore) primary
antibodies, followed by IR-Dye labeled secondary antibodies (Li-Cor). Fluorescence
was detected using Odyssey infrared fluorescence scanner (Li-Cor).
2.5. Gene expression assays
Cells were treated for 16h, then total cellular RNA was extracted using the
Purelink kit (Invitrogen). The RNA was reverse transcribed using the High Capacity
cDNA Reverse Transcription kit (Applied Biosystems), and then subject to TaqMan
real-time PCR. The gene expression assays (Applied Biosystems) used were PPAR
(Hs00234592 m1), CD36 (Hs00169627 m1), LXR (Hs00172885 m1), and 18S rRNA
(Hs99999901 s1). Gene expression was normalized to the level of 18S rRNA within
each sample using the relative CT method.
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Fig. 1. Relaxin activates PPAR activity through RXFP1. Cells expressing RXFP1 (HEK-RXFP1) or without RXFP1 (HEK) were treated with relaxin or related peptides. (A) Cells
transfected with ACO-PPRE and pRL-TK reporter plasmids were treated with the indicated concentrations of relaxin for 24h, then subject to firefly and renilla luciferase
assays. The data are expressed as the ACO-PPRE luciferase activity relative to that in untreated cells, mean± S.E.M. (N=3). (B) HEK-RXFP1 or HEK cells were treated with the
indicated concentrations of relaxin for 30min, then subject to cAMP quantitation. Data are expressed as the actual cAMP concentration (nM)mean± S.E.M. of triplicate wells.
(C) Cells were treated with 100nM relaxin, H3 relaxin or InsL3 for 24h or 30min for PPRE luciferase assay (N=3) or cAMP determination (triplicate wells), respectively.
2.6. Statistical analysis
Curve-fitting and statistical analysis was performed using Prism 5 software
(GraphPad). Differences were analyzed using one-way or two-way analysis of vari-
ance as appropriate,withBonferroni’s post-test.Data are expressedasmean± S.E.M.
of at least three independent determinations except as indicated in the figure leg-
ends.
3. Results
3.1. Relaxin increases PPAR transcriptional activity in
RXFP1-expressing cells
Activation of PPARs induces binding to peroxisome prolifera-
tor response elements (PPRE) in target gene promoters, resulting
in gene transcription. To determine the effect of relaxin on PPAR
activity, a reporter plasmid containing three tandem copies of the
PPRE from acyl-CoA oxidase upstream of the firefly luciferase gene
was used to monitor activation of PPAR. Relaxin treatment of HEK-
RXFP1 cells resulted in a concentration-dependent increase inPPAR
activity (Fig. 1A). The apparent EC50 was 22.39pM, with a max-
imal increase in PPRE transcriptional activity of approximately
two-fold. There was no response in the parental HEK cells (not
expressing RXFP1). Consistent with activation of RXFP1, relaxin
treatment increased cAMP production in HEK-RXFP1 cells, but not
cells lacking RXFP1 (Fig. 1B). The calculated pEC50 value for cAMP
stimulation was 214.7pM. The effect was specific to RXFP1 lig-
ands, as both relaxin and the alternative RXFP1 agonist H3 relaxin
(human relaxin-3) induced PPRE transcriptional activity, but the
relaxin-like peptide InsL3, which is the physiological ligand for
RXFP2, and has very low affinity for RXFP1, had no significant effect
(Fig. 1C).
3.2. Relaxin activates PPAR
The PPRE reporter plasmid used above is not specific, and can
be activated by PPAR, PPAR, or PPAR. To explore the poten-
tial role of each of the PPARs in the cell model, HEK-RXFP1 cells
were treated with PPAR subtype-specific agonists, with or with-
out relaxin. Agonists for either PPAR or PPAR (WY-14,643 and
GW0742, respectively) slightly increased the activity of the PPRE
reporter (Fig. 2). The combination of eitherWY-14,643 or GW0742
with relaxin resulted in PPRE transcriptional activity that did not
differ from relaxin alone. In contrast, agonists of PPAR (rosiglita-
zone and 15d-PGJ2) induced a much greater increase in activation
of the PPRE reporter. Furthermore, the combination of relaxin and
PPAR agonists resulted in an induction of PPRE that was signif-
icantly greater than either treatment alone. The low responses of
PPAR and PPAR to their agonists either alone or in combination
with relaxin make it unlikely that they are the target of the relaxin
effects on the PPRE reporter, while the greater response to PPAR
agonists makes it more likely that PPAR is the target of relaxin
signaling.
To confirm that the target of relaxin signaling was PPAR,
cells were infected with adenoviruses expressing either wild-type
(wtPPAR) or dominant-negative PPAR (dnPPAR). The dnPPAR
possesses DNA binding activity, but has reduced transcriptional
activity due to preferential binding to corepressors (Park et al.,
2003), and thus can inhibit the wtPPAR. Infection with wtPPAR
caused an increase in the basal and rosiglitazone-induced PPRE
transcriptional activation (Fig. 3). Relaxin also increased the acti-
vation of wtPPAR, as well as the residual activity in the presence
of the dnPPAR. However, when cells were coinfected with both
wtPPAR and dnPPAR, the response to both relaxin and rosigli-
tazone was greatly suppressed. To more directly identify PPAR as
the target of relaxin signaling, siRNAwasused to reduce the expres-
sion of PPAR. Introduction of PPAR siRNA, but not control siRNA,
Fig. 2. Relaxin increases the overall response to PPAR agonists. HEK-RXFP1 cells
were treated for 24hwith orwithout 1nM relaxin in the presence or absence of spe-
cific PPAR agonists, then subject to the PPRE luciferase assay. The agonists usedwere
WY-14,643 (WY, 2M) for PPAR; GW-0742 (GW, 10nM) for PPAR; and rosigli-
tazone (Rosi, 1M) or 15-deoxy-12,14-PGJ2 (PGJ2, 1M) for PPAR. The data are
expressed as the ACO-PPRE luciferase activity relative to that in untreated cells,
mean± S.E.M. (N=5). *p< .05 compared to corresponding agonist in the absence of
relaxin; #p< .05 compared to no treatment; †p< .05 compared to either relaxin or
corresponding agonist alone.
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Fig. 3. Effect of relaxin on wild-type and dominant-negative PPAR. HEK-RXFP1
cellswere infectedwith adenoviruses expressing-galactosidase (-Gal),wild-type
PPAR (WT), dominant-negative PPAR (DN) or WT:DN at a 1:2.5 ratio. Cells were
then treated with relaxin (1nM), rosiglitazone (1M), or vehicle for 24h, then sub-
ject to the PPRE luciferase assay. The data are expressed as the ACO-PPRE luciferase
activity relative to that in uninfected untreated cells. Data are mean± S.E.M., N=3.
*p< .001 compared to -Gal; †p< .01 compared to WT.
reduced the levelofPPARprotein inHEK-RXFP1cells (Fig. 4A). Fur-
thermore, in the presence of PPAR siRNA, transcription through
PPRE in response to relaxin or rosiglitazone was reduced, whereas
control siRNA had no effect (Fig. 4B).
To confirm that relaxin activation of PPAR resulted in acti-
vation of gene transcription, the ability of relaxin to induce the
expression of PPAR target genes was determined in HEK-RXFP1
cells. Both relaxin and rosiglitazone induced significant increases
in the expression levels of CD36 (Fig. 5A). The expression level of
LXR was significantly increased by rosiglitazone, and was also
increased by relaxin, although not to the point of statistical signif-
icance. To assess the effect of relaxin on cells naturally expressing
RXFP1, a similar experiment was performed in THP-1 cells, a
monocyte/macrophage cell line responsive to relaxin. Treatment
of THP-1 cells with relaxin significantly increased the expression
of both CD36 and LXR (Fig. 5B), similar to the response induced
by rosiglitazone.
3.3. Relaxin does not increase PPAR mRNA or protein levels
The relaxin effects onPPAR activitydidnot require the addition
of exogenous PPAR agonists, raising the possibility that relaxin
increased the expression or stability of PPAR. However, using
real-time RT-PCR, it was found that relaxin, rosiglitazone, or their
combination did not significantly increase PPAR mRNA in HEK-
RXFP1 cells (Fig. 6B). Likewise, no change was detectable in the
Fig. 4. Knockdown of PPAR reduces the response to relaxin. PPAR-specific or
nontargeting control siRNAwere introduced into HEK-RXFP1 cells by nucleofection.
(A) After 24h, a portion of the cells were lysed and subject to Western blot analysis
to determine the levels of PPAR or GAPDH. (B) The remaining cells were treated
with relaxin (1nM), rosiglitazone (1M), or vehicle for 24h, then subject to the
PPRE luciferase assay. The data are expressed as the ACO-PPRE luciferase activity
relative to untreated cells, mean± S.E.M. of six wells per condition. The experiment
was repeated three times, and a representative result is shown. *p< .05, **p< .001
compared with untreated control; †p< .001 compared to nontargeting siRNA under
the same treatment.
protein levels of PPAR (Fig. 6A). Therefore, the increase in PPRE
transcriptional activity in response to relaxin in HEK-RXFP1 was
not due to increased expression or stability of PPAR.
3.4. Relaxin activation of PPAR is ligand-independent
Relaxin activation of PPAR did not require exogenous PPAR
ligands, and did not increase PPAR levels. Therefore, it is possible
that relaxin induces production of an endogenous PPAR ligand, or
causes ligand-independent activation of PPAR. To address these
possibilities, a covalent modifier of PPAR that prevents ligand
binding (GW9662) was used to block ligand-dependent activation
of PPAR transcriptional activity. As expected, PPAR activation by
rosiglitazonewas blocked byGW9662 (Fig. 7). In contrast, GW9662
had no effect on relaxin signaling, and only partially blocked the
Fig. 5. Relaxin increases the expression of PPAR target genes. Cells were treated with 1nM relaxin (Rlx) or 1M rosiglitazone (Rosi) for 16h. Total RNA was extracted, and
the mRNA for CD36 and LXR were quantified by real-time RT-PCR, and normalized to the level of 18S rRNA using the relative CT method. The cell lines tested were (A)
HEK-RXFP1 cells, and (B) THP-1 monocytes. Data are expressed as the percent gene expression compared with untreated cells, mean± S.E.M., N=3. *p< .05 compared with
untreated cells.
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Fig. 6. Relaxin does not increase PPARmRNA or protein. (A) HEK-RXFP1 cells were
treated with 1nM relaxin (Rlx), 1M rosiglitazone (Rosi), or both for 24h. Total
protein was extracted and analyzed by Western blotting for PPAR or GAPDH as
indicated. Blot shown is representative of at least four independent experiments. (B)
HEK-RXFP1 cells were treated with 1nM relaxin (Rlx) or 1M rosiglitazone (Rosi),
or both for 16h. Total RNA was extracted, and the mRNA for PPARwas quantified
by real-time RT-PCR, and normalized to the level of 18S rRNA using the relative CT
method. Data shown are mean± S.E.M., N=3.
combined effect of relaxin and rosiglitazone, reducing the response
to the level achieved by relaxin alone. Therefore, this data suggests
that relaxin does not increase the level of an endogenous PPAR lig-
and in these cells, butmay instead increase PPAR activity through
a ligand-independent mechanism.
Fig. 7. Relaxin activation of PPAR is not ligand-dependent. HEK-RXFP1 cells were
treated for 24h with 1nM relaxin (Rlx), 1M rosiglitazone (Rosi), or both, in the
presence and absence of the inhibitor of PPAR ligand binding (GW9662, 100nM)
or vehicle control (DMSO) for 24h, then subject to thePPRE luciferase assay. Thedata
are expressed as the ACO-PPRE luciferase activity relative to that of untreated cells,
mean± S.E.M.,N=4. *p< .001 compared to untreated controls; #p< .01 compared to
GW9662 alone; †p< .05.
4. Discussion
We have shown that relaxin activates transcriptional activity
through PPRE in cells expressing RXFP1. Despite the low expres-
sion levels of PPARs in these cells, relaxin consistently increased
activity through the PPRE reporter vector, with an efficacy equal to
or greater than the PPAR agonists. The relaxin effect was reduced
in the presence of dominant-negative PPAR, or by siRNA silenc-
ing. Finally, relaxin treatment resulted in increased expression of
the PPAR target genes CD36 and LXR, both in cells overexpress-
ing RXFP1 and cells naturally expressing the receptor. Therefore,
these are the first experiments demonstrating activation of PPAR
transcriptional activity by relaxin.
The primary relaxin receptor is RXFP1, but potential alternative
receptors have been identified. Experiments in vitro have shown
that relaxin can also activate RXFP2, although the relevance of this
interaction has not been demonstrated in vivo, and InsL3 is the cog-
nate ligand for RXFP2 (Bogatcheva et al., 2003; Hsu et al., 2002). In
some cells, relaxin can activate the glucocorticoid receptor, appar-
ently in an RXFP1-independent manner (Dschietzig et al., 2005).
In our studies, PPAR was activated in HEK-293T cells express-
ing RXFP1, but not in the untransfected cells that do not express
RXFP1 or RXFP2. The alternative RXFP1 ligand relaxin-3 also acti-
vated PPAR, but InsL3,whichhas extremely lowaffinity for RXFP1,
had no effect. Therefore, the activation of PPAR required the pres-
ence of RXFP1, and was not the result of action through alternative
relaxin receptors or glucocorticoid receptor activation.
The combination of relaxin and rosiglitazone caused a greater
increase in PPAR activity than either agent alone, suggesting that
they were acting through different mechanisms. Importantly, this
relaxin effect did not require the addition of exogenous PPAR
ligands. Therefore it was possible that relaxin was increasing the
expression of PPAR or increasing the stability of PPAR protein.
However, when PPAR was overexpressed, the relaxin effect was
maintained. There was no change in PPAR gene expression in
response to relaxin, and no increase in the levels of PPAR pro-
tein. Another possible mechanism for relaxin activation of PPAR
activity could be increased production of an endogenous PPAR
ligand. Our data suggests that this is not the responsible mech-
anism. Treatment with GW9662, a covalent modifier of PPAR
that prevents ligand-dependent activation, effectively blocked
rosiglitazone-induced PPAR. Conversely, the effect of relaxin was
not blocked by GW9662. If relaxin increased the production of an
endogenous ligand, thenGW9662 shouldhaveblocked relaxin acti-
vation of PPAR. Therefore, othermechanismsmay be responsible.
As stated above, the ability of relaxin to activate PPAR did not
require the addition of exogenous PPAR agonists. Furthermore,
unlike the results using the PPRE reporter vector, the expres-
sion of the PPAR target genes CD36 and LXR was greater in
response to rosiglitazone than to relaxin, providing further evi-
dence that relaxin and rosiglitazone act on PPAR throughdifferent
mechanisms. Together with the insensitivity to GW9662, the data
suggests that relaxin may be acting to stimulate PPAR through
a ligand-independent mechanism, an area of increasing interest
(Xu and Li, 2008). In addition to its heterodimerization partner
RXR, PPAR associates with a number of transcriptional coac-
tivators and corepressors, which can regulate its activity and
specificity both in the absence andpresenceof PPAR ligands (Feige
and Auwerx, 2007; Lonard and O’Malley, 2007; Puigserver and
Spiegelman, 2003). For example, PPAR association with the coac-
tivators PPAR coactivator 1 (PGC1) or p300 results in increased
PPAR ligand-independent transcriptional activity, and altered tar-
get gene specificity (Gelman et al., 1999; Puigserver et al., 1998).
In addition, the activity of PPAR, or its binding to coactivators
and corepressors can be regulated by phosphorylation (Burns and
Vanden Heuvel, 2007). Further study is needed to determine if
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relaxin activation of PPAR transcriptional activity involves one of
these mechanisms.
ThroughRXFP1, relaxin activates the cAMPpathway (Halls et al.,
2007; Sherwood, 2004). We have found that the EC50 for relaxin-
activatedPPAR transcriptional activitywasapproximately10-fold
lower than its ability to elevate cAMP levels. This finding raises the
possibility that relaxin activates PPAR through additional signal-
ing pathways. Indeed, relaxin has been shown to act through nitric
oxide, tyrosine kinase, and mitogen-activated protein kinase path-
ways (Anand-Ivell et al., 2007; Baccari and Bani, 2008; Dschietzig
et al., 2003; Mookerjee et al., 2009). Importantly, these same path-
ways have all been implicated in the regulation of PPAR activity
(Burns andVandenHeuvel, 2007; Lazennec et al., 2000; Ptasinska et
al., 2007). Indeed, there is considerable overlap in the properties of
relaxin and PPAR in the response of fibroblasts to fibrotic stimuli.
For example, both relaxin andPPAR agonists reduced the response
to the profibrotic cytokine TGF in skin (Unemori and Amento,
1990; Ghosh et al., 2004), lung (Burgess et al., 2005; Unemori et al.,
1996), and renal fibroblasts (Masterson et al., 2004; Zafiriou et al.,
2005), and both agents have been effective in treatment of fibrosis
in vivo (Samuel, 2005;Bennett, 2009;Michalik, 2006). Interestingly,
recent studyprovidedevidence that in renalfibroblasts, relaxin acts
to decrease the TGF-induced fibrotic phenotype throughmultiple
mechanisms including cAMP, nitric oxide, and mitogen-activated
protein kinase (Mookerjee et al., 2009), providing further support
for cross-talk between relaxin and PPAR signaling.
In summary, we have provided the first evidence that relaxin
signaling through RXFP1 activates the transcriptional activity of
PPAR. These findings provide a possible mechanism for the antifi-
brotic effects of relaxin. Because RXFP1 expression appears to be
lacking in glucoregulatory insulin-sensitive cells (Hsu et al., 2003;
Kamat et al., 2004), relaxin treatment may be an approach to the
treatment of fibrosis by activation of PPAR, but without the glu-
coregulatory andadipogenic effects of thiazolidinediones andother
PPAR agonists.
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